

(12) **United States Patent**
Zarnitsyn et al.

(10) **Patent No.:** **US 9,636,332 B2**
(45) **Date of Patent:** ***May 2, 2017**

(54) **METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS**

(71) Applicant: **Clearside Biomedical, Inc.**, Alpharetta, GA (US)

(72) Inventors: **Vladimir Zarnitsyn**, Atlanta, GA (US);
Samirkumar Patel, Atlanta, GA (US);
Daniel White, Suwanee, GA (US);
Glenn Noronha, Atlanta, GA (US);
Brian Burke, Cary, NC (US)

(73) Assignee: **CLEARSIDE BIOMEDICAL, INC.**, Alpharetta, GA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/001,610**

(22) Filed: **Jan. 20, 2016**

(65) **Prior Publication Data**

US 2016/0206628 A1 Jul. 21, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/441,151, filed as application No. PCT/US2013/069156 on Nov. 8, 2013.

(Continued)

(51) **Int. Cl.**

A61K 31/4439 (2006.01)

A61K 47/12 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61K 31/4439** (2013.01); **A61K 9/0019** (2013.01); **A61K 9/0048** (2013.01);

(Continued)

(58) **Field of Classification Search**

CPC A61K 31/573; A61K 2300/00; A61K 2039/505; A61K 2039/54; A61K 31/4439;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,187,259 A 1/1940 Barnhart
3,477,432 A 11/1969 Shaw
(Continued)

FOREIGN PATENT DOCUMENTS

CN 1706365 12/2005
CN 1736474 2/2006
(Continued)

OTHER PUBLICATIONS

Ozkiris, Abdullah ("Intravitreal Triamcinolone Acetonide Injection for the Treatment of Posterior Uveitis," Ocular Immunology and Inflammation, vol. 14, 2006—Issue 4, pp. 233-238—Abstract attached).*

(Continued)

Primary Examiner — Aradhana Sasan

(74) *Attorney, Agent, or Firm* — Cooley LLP

(57)

ABSTRACT

Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

17 Claims, 38 Drawing Sheets

